Stockscreener 앱 받기
17.59
2.57%
0.44
시장 영업 전:
18.20
0.61
+3.47%
전일 마감가:
$17.15
열려 있는:
$17.25
하루 거래량:
156.13K
Relative Volume:
0.54
시가총액:
$360.22M
수익:
-
순이익/손실:
$-75.86M
주가수익비율:
-3.4444
EPS:
-5.1069
순현금흐름:
$-59.39M
1주 성능:
+4.58%
1개월 성능:
-23.89%
6개월 성능:
-28.93%
1년 성능:
+42.08%
1일 변동 폭
$17.17
$17.89
1주일 범위
$16.60
$18.49
52주 변동 폭
$9.10
$35.80
Forte Biosciences Inc Stock (FBRX) Company Profile
명칭
Forte Biosciences Inc
전화
(310) 618-6994
주소
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
17.59 | 369.64M | 0 | -75.86M | -59.39M | -5.1069 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 개시 | Evercore ISI | Outperform |
| 2025-08-18 | 개시 | Guggenheim | Buy |
| 2025-01-21 | 개시 | TD Cowen | Buy |
| 2024-04-08 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | 업그레이드 | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | 다운그레이드 | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | 다운그레이드 | Truist | Buy → Hold |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-03-26 | 개시 | Citigroup | Buy |
| 2020-08-28 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | 개시 | Truist | Buy |
모두보기
Forte Biosciences Inc 주식(FBRX)의 최신 뉴스
One Forte Biosciences Insider Raised Stake By 30% In Previous Year - Yahoo Finance
[EFFECT] Forte Biosciences, Inc. SEC Filing - Stock Titan
FBRX Q1 2026 Earnings: Wider-than-Expected Loss as Biotech Continues DevelopmentMargin Guidance - newsline.com
Trading Systems Reacting to (FBRX) Volatility - Stock Traders Daily
Millennium Group (FBRX) reports shared control of 1,062,182 shares - Stock Titan
Forte Biosciences (FBRX) Edges Lower Amid Sector Volatility, Key Support HoldsSmart Money Flow Stocks - newsline.com
Number of shareholders of Forte Biosciences Inc. – GETTEX:37T - TradingView
Forte Biosciences (FBRX) Slips 1% as Stock Consolidates Between Key Support and ResistanceTrend Continuation Trade - newsline.com
Forte Biosciences (NASDAQ: FBRX) files $500M shelf to sell securities - Stock Titan
Forte Biosciences Shareholders Approve Directors and Governance Items - TipRanks
Forte Biosciences (NASDAQ: FBRX) director receives 18,353 RSU equity award - Stock Titan
Forte Biosciences (NASDAQ: FBRX) files $500M shelf; highlights FB102 clinical wins - Stock Titan
Forte Biosciences (FBRX) director awarded 18,353 restricted stock units in equity grant - Stock Titan
Forte Biosciences (FBRX) director granted 18,353 RSUs in equity award - Stock Titan
Forte Biosciences (FBRX) director awarded 18,353 RSUs vesting after 2026 meeting - Stock Titan
Director at Forte Biosciences (NASDAQ: FBRX) awarded 18,353 RSUs as equity grant - Stock Titan
Forte Biosciences (FBRX) awards 18,353 RSUs to director Steven Kornfeld - Stock Titan
Forte Biosciences (FBRX) stockholders approve amended 2021 equity incentive plan - Stock Titan
Insider Buyers Lose Additional US$69k As Forte Biosciences Dips To US$466m - Moomoo
FBRX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Clinical Progress - newsline.com
Forte Biosciences (FBRX) price target increased by 19.72% to 65.02 - MSN
Forte Biosciences Slides As Insider Purchases Lose Another US$70k - simplywall.st
Forte Biosciences (FBRX) Tumbles 8% as Bears Test Support at $18.12Insider Buying Alerts - newsline.com
Forte Biosciences Inc stock (US34960P1012): shares slip after recent Q1 loss and high volatility - AD HOC NEWS
FBRX - Finviz
FBRX Q1 2026 Earnings: Pre-Revenue Biotech Reports Narrow EPS Miss Amid Ongoing DevelopmentSurprise Factor Analysis - newsline.com
Forte Biosciences Q1 2026 Earnings: Pre-revenue Biotech Misses EPS Estimates; Stock Dips on Narrower Loss MissTech Earnings Analysis - The Legal Advocate
FBRX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Pre-Revenue Biotech RealityLive Trade Sharing - Newser
Forte Biosciences stock (US34960P1012): Q1 update keeps focus on skin disease pipeline - AD HOC NEWS
(FBRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Forte Biosciences Inc stock (US34960P1012): clinical pivot and cash focus keep biotech investors ale - AD HOC NEWS
Forte Biosciences stock (US34960P1012): volatile biotech after recent sell-off tests investor nerves - AD HOC NEWS
Forte Biosciences stock (US34960P1012): New 13G filings highlight major holders - AD HOC NEWS
Forte Biosciences Stock: Targeting Celiac Disease (NASDAQ:FBRX) - Seeking Alpha
OrbiMed entities hold 5.8% of Forte Biosciences (FBRX), ownership split disclosed - Stock Titan
Point72 entities report 0% ownership in Forte Biosciences (FBRX) - Stock Titan
MPM BioImpact LLC takes a 7.2% position in Forte Biosciences (NASDAQ: FBRX) - Stock Titan
Alger Associates (NASDAQ: FBRX) reports 1.27M shares; 10.2% stake - Stock Titan
Janus Henderson (FBRX) discloses 9.99% holding; 299,798 pre-funded warrants - Stock Titan
Forte Biosciences (NASDAQ: FBRX) deepens Q1 loss while FB102 wins Fast Track - Stock Titan
Affinity Asset Advisors takes 7.3% stake in Forte Biosciences (NASDAQ: FBRX) - Stock Titan
Forte Biosciences stock (US34960P1012): Q1 2026 earnings report upcoming - AD HOC NEWS
Forte Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Adage (FBRX) files Schedule 13G reporting 950,000-share stake - Stock Titan
Forte Biosciences stock (US34960P1012): Q1 2026 results and FDA Fast Track for FB102 - AD HOC NEWS
Chardan Capital Maintains Forte Biosciences(FBRX.US) With Buy Rating, Maintains Target Price $61 - Moomoo
MSN Money - MSN
TD Cowen Maintains Forte Biosciences(FBRX.US) With Buy Rating - Moomoo
Forte Biosciences Grants 66,667 RSUs to New Employee as Inducement - geneonline.com
New Forte Biosciences hire gets 50K options, 50K RSUs to join - Stock Titan
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - The Joplin Globe
Forte Biosciences Inc (FBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Forte Biosciences Inc 주식 (FBRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '26 |
Option Exercise |
0.00 |
375 |
0 |
41,895 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Dec 30 '25 |
Buy |
26.33 |
9,680 |
254,833 |
41,520 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,974 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
82,190 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,733 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
81,038 |
2.60%
0.94%
자본화:
|
볼륨(24시간):